US4690935A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of tumor growth and metastasis with calcium channel blocker compounds
Assignee: Wayne State University
•
Filing: 1983-03-31
•
Granted: 1987-09-01
•
Expires: 2003-03-31
Abstract
Abstract The use of calcium channel blocker compounds as antitumor and antimetastatic agents in mammals in vivo and in standard laboratory experimets with tumor cells in vitro is described. In particular the use of nimodipine (Bay e 9736) or nifedipine (Bay a 1040) and structurally related compounds as described.
Inventors
- 👤 John D. Taylor
- 👤 Kenneth V. Honn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/55; A61P; A61P35/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
118 words
A method for reducing interaction between blood platelets and malignant tumors present in the blood and resulting attachment of the tumors with the platelets in blood vessels in a mammal which comprises: administering to a mammal in need thereof an effective amount of a calcium channel blocker compound selected from the group consisting of phenylalkyamines, benzothiapenes, diphenylalkylamines and 1,4-dihydropyridines which is substituted in the 4-position which reduces the interaction between the platelets and the tumors and resulting attachment of the tumors with the platelets in the blood vessels without treating the tumors to thereby interfere with the metastatic cascade in the mammal and wherein in vitro the calcium channel blocker compounds prevent aggregation of tumor cells and platelets.
Claim 2
Independent Claim
118 words
A method for reducing interaction between blood platelets and malignant tumors present in the blood and resulting attachment of the tumors with the platelets in blood vessels in a mammal which comprises: administering to a mammal in need thereof an effective amount of a calcium channel blocker compound selected from the group consisting of phenylalkyamines, benzothiapenes, diphenylalkylamines and 1,4-dihydropyridines which is substituted in the 4-position which reduces the interaction between the platelets and the tumors and resulting attachment of the tumors with the platelets in the blood vessels without treating the tumors to thereby interfere with the metastatic cascade in the mammal and wherein in vitro the calcium channel blocker compounds prevent aggregation of tumor cells and platelets.
Claim 3
Dependent Claim
21 words
A method as claimed in claim 1 wherein the tumor is produced by B-16 amelanotic melanoma in mice as the mammal.
Claim 4
Dependent Claim
17 words
The method of claim 1 wherein the compound is a 1,4-dihydropyridine which is substituted in the 4-position.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein the compound is 1,4-dihydro-2-,6-dimethyl-4-(3'-nitrophenyl)-pyridine-3-(low er alkyl ester)-5-(lower alkyl ester), wherein lower alkyl contains between 1 to 6 carbon atoms.
Claim 6
Dependent Claim
10 words
The method of claim 1 wherein the compound is nifedipine.
Claim 7
Dependent Claim
13 words
The method of claim 1 wherein the calcium channel blocker compound is nimodipine.
Claim 8
Dependent Claim
10 words
The method of claim 1 wherein the administration is oral.
References Cited (Backward Citations)
GB2018134A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-08-31 | 1991-03-02 | 1991-09-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-08-31 | 1995-03-02 | 1995-09-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-08-31 | 1999-03-02 | 1999-09-01 | $7700.00 | Window Closed / Lapsed |